Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.

@article{Brodbeck2008RosiglitazoneID,
  title={Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.},
  author={Jens Brodbeck and Maureen E. Balestra and Ann M Saunders and A. D. Roses and Robert W. Mahley and Ya-dong Huang},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 4},
  pages={1343-6}
}
Convergent evidence has revealed an association between insulin resistance and Alzheimer's disease (AD), and the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, an insulin sensitizer and mitochondrial activator, improves cognition in patients with early or mild-to-moderate AD. Apolipoprotein (apo) E4, a major genetic risk factor for AD, exerts neuropathological effects through multiple pathways, including impairment of dendritic spine structure and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-5 of 5 references

Neurology 66(Suppl 1):S79–S85

  • Y Huang
  • 2006

Pharmacogenomics J 6:246–254

  • ME Risner, AM Saunders, +6 authors AD Roses
  • 2006

Anticancer Res 24:3–9

  • MA Lea, M Sura, C Desbordes
  • 2004

CNS Drugs 17:27–45

  • GS Watson, S Craft
  • 2003

Diabetic Med 16:179–192

  • C Day
  • 1999

Similar Papers

Loading similar papers…